Explore frontline CLL therapy choices: durable BTK inhibitors vs fixed venetoclax regimens, emerging combos, and what long-term safety data reveal.
Reassessing the Continuous-vs-Fixed-Duration Debate in Frontline Chronic Lymphocytic Leukemia
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
3
Micvotabart Pelidotin Monotherapy Yields Responses in Pretreated Recurrent/Metastatic HNSCC
4
Namodenoson Generates Longer-Than-Anticipated OS Advanced HCC
5